Ixchelsis

About:

Ixchelsis develops an oxytocin receptor antagonist for the treatment of premature ejaculation.

Top Investors: Pfizer Venture Investments, TVM Capital Life Science

Description:

Ixchelsis Ltd is a clinical-stage biotechnology company developing an oxytocin receptor antagonist (IX-01) for the treatment of premature ejaculation (PE). IX-01 is a clinical stage asset that has the potential to be the best in class pharmacological approach for the treatment of PE. To date IX-01 has completed a Phase 1 single ascending dose study in healthy male volunteers and is currently being progressed through to clinical proof of concept (POC). Ixchelsis is funded by TVM Life Sciences Ventures VII and is lead by an excellent Management team with extensive experience in pharmaceutical R&D, particularly in the male sexual health therapeutic area.

Total Funding Amount:

$12M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Sandwich, Kent, United Kingdom

Founded Date:

2011-01-01

Founders:

Gary Muirhead, Liz Littlewood

Number of Employees:

1-10

Last Funding Date:

2016-12-05

IPO Status:

Private

Industries: